New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
09:03 EDTINOInovio repsonds to third party article regarding immunotherapy study
Inovio announced that it wishes to clarify that a third party article published on June 10, was misrepresentative of facts and can only be taken as malicious. The company said the referenced article does not reflect the progress, status, and potential of Inovio's active immune therapy technology and products and is rife with false and misleading conjecture. Inovio has indicated that it expects to report mid-year the top-line results of its phase II clinical trial evaluating VGX-3100 for the treatment of cervical dysplasia. Inovio said it designed the double blind, placebo controlled phase II study to comprehensively measure efficacy, HPV viral clearance, immunogenicity, and safety. At this time the data remains blinded and the company aims to report this data by the end of July. Inovio adds, "We are hopeful that these results could lead to a novel therapeutic option for women to avoid the invasive current surgical procedure. There exists the prospect that our immunotherapy approach may eliminate the presence of HPV virus to minimize future recurrences."
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
08:41 EDTINOInovio announces dMAb targeting dengue virus provided protection in mice
Subscribe for More Information
July 27, 2015
08:10 EDTINOInovio initiates clinical trial of INO-5150 DNA immunotherapy
Subscribe for More Information
July 23, 2015
08:18 EDTINOInovio, EORTC to collaborate on Phase 2 cervical cancer trial
Inovio announced it is collaborating with the European Organization for Research and Treatment of Cancer, or EORTC, to evaluate Inovio's immunotherapy, INO-3112, in combination with traditional chemo-radiotherapy for the treatment of patients with locally advanced stage cervical cancer. The trial, primarily funded by the EORTC, is expected to begin by the end of the year. A partnership with the EORTC will offer Inovio clinical trial efficiency and speed in recruiting patients in Europe and in obtaining and analyzing results. The EORTC encompasses all aspects of cancer research, from translational research and new drug development to large phase III clinical trials and meta-analyses. EORTC is the only organization which carries out clinical studies throughout Europe for all types of cancer. Collaboration with the EORTC also leverages their connections to a network of more than 2,500 pre-clinical scientists and oncologists in more than 300 hospitals in over 30 countries.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use